Lobe Sciences Releases Third Quarter 2026 Financial Results

Lobe Sciences Ltd., a Vancouver-based biopharmaceutical company, announced its unaudited interim financial results for Q3 2026, ending May 31. Known for advancing therapeutic programs through subsidiaries, Lobe maintained a disciplined capital allocation approach, aiming for long-term shareholder value.

The financial highlights reveal cash reserves at $1.5 million, supplemented by $3.7 million in short-term investments. The company reported a net working capital of $3.2 million and research and development expenses increased significantly to $2.4 million, reflecting progress in key programs. A net loss of $4.8 million for the quarter was attributed primarily to heightened investments in R&D and infrastructure.

Lobe's directors and officers opted for increased equity stakes by settling fees through shares. The company also completed a non-brokered private placement raising $950,000 for advancing its S-100 drug candidate against sickle cell disease. An additional placement is expected to close soon, targeting further development and cash reserves.